Last updated: February 23, 2026
What is NDC 59310-0302?
NDC 59310-0302 refers to Venclexta (venetoclax), a targeted therapy for hematologic malignancies. Approved by the FDA in April 2016, it is indicated for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) in specific settings.
Market Landscape
Key Competitors
Venetoclax competes primarily with other BCL-2 inhibitors and standard chemotherapies. Major competitors include:
- Ibrutinib (Imbruvica)
- Acalabrutinib (Calquence)
- Chemotherapy regimens (e.g., FCR for CLL)
Market Size
- The U.S. hematologic oncology drug market was valued at approximately USD 1.4 billion in 2021.
- Venetoclax's sales reached USD 1.2 billion globally in 2022.[1]
- The drug’s main revenue driver is coverage for CLL and AML, with expanding use in combination therapies.
Prescriber Adoption
- Initial adoption was driven by high efficacy in relapsed/refractory CLL.
- Occurs predominantly in specialty oncology centers.
- Use in combination with rituximab and azacitidine has shown increased prescribing.
Regulatory and Reimbursement Factors
- FDA approved for multiple indications; expanded labels and combination approvals increase market penetration.
- Reimbursement depends heavily on CMS and private payers' coverage decisions.
Price Structure Analysis
Current Pricing
- The wholesale acquisition cost (WAC) for Venclexta is approximately USD 8,000 per 30-day supply.[2]
- Price varies based on formulation (tablet strength), patient co-pay assistance, and insurance coverage.
Pricing Comparison
| Drug |
Approximate Monthly Cost |
Indication |
| Venclexta |
USD 8,000 |
CLL, AML |
| Imbruvica |
USD 9,500 |
CLL, MCL, WM |
| Calquence |
USD 9,000 |
CLL, MCL |
Cost Drivers
- High drug efficacy and targeted mechanism justify premium pricing.
- Patent exclusivity extends until 2032.
- Pricing varies across regions; U.S. prices are generally higher than international markets.
Future Price Projections
Market Growth Assumptions
- CAGR of 12% from 2023 to 2027.
- Expanded indications and combination therapies drive volume increases.
- Price adjustments influenced by biosimilar entry and payor negotiations.
Price Trends
- Predicted stabilization of WAC at USD 8,200–USD 8,500 by 2025, driven by inflation and market dynamics.
- Competition from biosimilars or complementary therapies could exert downward pressure after patent expiry.
Revenue Forecasts
| Year |
Estimated Global Sales (USD Billions) |
Notes |
| 2023 |
1.4 |
Continued adoption in new indications |
| 2025 |
1.8 |
Expanded use in AML and combination therapies |
| 2027 |
2.3 |
Entry of biosimilars or new competitors if approved |
Strategic Considerations
- Patent protection until 2032 limits generic competition.
- Pricing strategies focus on staging increases aligned with expanded indications.
- Payer negotiations will be essential to maintain margins amid increasing competition.
- Market expansion opportunities exist in Europe, Asia, and emerging markets, where prices are typically lower but growth potential significant.
Key Takeaways
- NDC 59310-0302 (Venclexta) commands a premium price, supported by high efficacy and targeted therapy status.
- The global market size neared USD 1.4 billion in 2022, with sustained growth driven by expanding indications.
- Price projections suggest stabilization with slight increases; competition and biosimilars could pressure prices post-2032.
- Revenue growth relies on broader adoption, combination approvals, and market penetration in non-U.S. regions.
FAQs
1. When is patent expiry for Venclexta?
Patent protection lasts until 2032, after which generic versions could enter the market.
2. How do combination therapies affect Venclexta's pricing?
Combination regimens might increase overall treatment costs but can expand usage, potentially leading to volume-driven revenue increases.
3. What are the main factors influencing future price increases?
Market expansion, new indications, inflation, and payor negotiations.
4. Are biosimilars expected to impact Venclexta prices?
Not biosimilars, as it is a small molecule; but biosimilar competitors for drugs in same class could influence overall pricing strategies.
5. Which regions offer the highest pricing potential?
The U.S. retains the highest prices, with significant growth opportunities in Europe, Asia, and emerging markets.
References
- IQVIA. (2022). Global Oncology Market Data.
- GoodRx. (2023). Venclexta Price Comparison.
- FDA. (2016). Venclexta (venetoclax) approval details.
[1] IQVIA (2022). Global Oncology Market Data.
[2] GoodRx (2023). Venclexta Price Comparison.
[3] FDA (2016). Venclexta (venetoclax) approval details.
